Insulin resistance is associated with microangiopathy in type 1 diabetic patients treated with intensive insulin therapy from the onset of disease

Experimental and Clinical Endocrinology and Diabetes

Volumn 118, Issue 8, 2010, Pages 478-484

  Uruska, A ^a   Araszkiewicz, A ^a   Zozulinska Ziolkiewicz, D ^a   Uruski, P ^a   Wierusz Wysocka, B ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

diabetes mellitus type 1; glucose disposal rate; insulin resistance; microangiopathy; risk factor

Indexed keywords

TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL FEATURE; DIABETIC MICROANGIOPATHY; DISEASE DURATION; FEMALE; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN TREATMENT; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT GAIN;

ADULT; AGE OF ONSET; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIPIDS; MALE; METABOLIC SYNDROME X; WEIGHT GAIN;

EID: 77956948342     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0030-1249635     Document Type: Article

References (34)

1. Alberti KGMM, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group The metabolic syndrome a new worldwide definition. Lancet 2005 366 1059-10621
2. Araszkiewicz A, Zozulinska-Ziolkiewicz D, Trepinska M, et al. High knowledge about diabetes decreases the likelihood of retinopathy in type 1 diabetic patients treated with intensive insulin therapy from the onset of the disease. Arch Med Sci 2005 1 205-210
3. Araszkiewicz A, Zozulinska-Ziolkiewicz D, Trepinska M, etal. Knowledge after five-day teaching program in intensive insulin therapy performed at the onset of type 1 diabetes influences the development of late diabetic complications. Diabetes Res Clin Pract. 2008 81 61-67
4. Arkkila PE, Koskinen PJ, Kantola IM, et al. Diabetic complications are associated with liver enzyme activities in people with type 1 diabetes. Diabetes Res Clin Pract 2001 52 113-118
5. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes 2005 54 1615-1625
6. Bruno G, Fornengo P, Novelli G, et al. C-reactive protein and 5-year survival in type 2 diabetes: the Casale Monferrato Study. Diabetes 2009 58 926-933
7. Chaturvedi N, Sjoelie AK, Porta M, et al. EURODIAB Prospective Complications Study: Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care 2001 24 2 284-289
8. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979 237 E214-E223
9. Ekstrand AV, Groop PH, Grönhagen-Riska C. Insulin resistance precedes microalbuminuria in patients with insulin-dependent diabetes mellitus. Nephrol Dial Transplant 1998 13 3079-3083
10. Fernndez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003 24 278-301
11. Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: double diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2007 30 707-712
12. Koivisto VA, Stevens LK, Mattock M, et al. The EURODIAB IDDM Complications Study Group. Cardiovascular disease and its risk factors in IDDM in Europe. Diabetes Care 1996 19 689-697
13. Krcma M, Cechurova D, Jankovec Z, et al. Effect of mild increase of physical activity on microvasculary reactivity in obese subjects with diabetes mellitus type 2. Exp Clin Endocrinol Diabetes 2009 117 150-152
14. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999 130 461-470
15. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: prospective studies of Pima Indians. N Engl J Med 1993 329 1988-1992
16. McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003 139 802-809
17. Müller UA, Femerling M, Reinauer KM, et al. Intensified treatment and education of type 1 diabetes as clinical routine A nationwide quality-circle experience in Germany. ASD (the Working Group on Structured Diabetes Therapy of the German Diabetes Association). Diabetes Care 1999 22 B29-B34
18. Nelson RG, Tuttle KR. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007 49 S12-S154
19. Orchard TJ, Chang YF, Ferrell RE, et al. Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int 2002 62 963-970
20. Orchard TJ, Olson JC, Erbey JR, et al. Insulin resistance-related factors, but not glycaemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2003 26 1374-1379
21. Perry IJ, Wannamethee SG, Shaper AG. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care 1998 21 732-737
22. Penn R, Worthington DJ. Is serum gamma-glutamyltransferase a misleading test? Br Med J (Clin Res Ed) 1983 286 531-535
23. Reaven G. Banting Lecture 1988: Role of insulin resistance in human disease. Diabetes 1988 37 1595-1607
24. Sainaghi PP, Castello L, Bergamasco L, et al. Metabolic characteristics of glucose intolerance: the critical role of obesity. Exp Clin Endocrinol Diabetes 2008 116 86-93
25. Savage DB, Petersen KF, Shulman GI. Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension 2005 45 828-833
26. Stern SE, Williams K, Ferrannini E, et al. Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 2005 54 333-339
27. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 329 977-986
28. Thorn LM, Forsblom C, Fagerudd J, et al. FinnDiane Study Group Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycaemic control (the FinnDiane study). Diabetes Care 2005 28 2019-2024
29. Wannamethee SG, Shaper AG, Lennon L, et al. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 2005 28 2913-2918
30. Williams KV, Erbey JR, Becker D, et al. Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 2000 49 626-632
31. Yip J, Mattock MB, Morocutti A, et al. Insulin resistance in insulin-dependent diabetic patients with microalbuminuria. Lancet 1993 342 883-887
32. Yki-Järvinen H. Glucose toxicity. Endocr Rev 1992 13 415-431
33. Yki-Järvinen H, Koivisto VA. Continuous subcutaneous insulin infusion therapy decreases insulin resistance in type 1 diabetes. J Clin. Endocrinol Metab 1984 58 659-666
34. Tiikkainen M, Bergholm R, Vehkavaara S, et al. Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes 2003 52 701-707